Nanoviricides Stock Price, News & Analysis

NanoViricides (NYSE:NNVC) has detailed the significant market potential of its broad-spectrum antiviral drug NV-387, which has shown effectiveness against multiple viruses including Influenza, Coronaviruses, RSV, MPox, and Measles. The company is advancing toward a Phase II clinical trial for MPox treatment, where NV-387 could become the first approved drug for this indication.

The drug's potential extends to pandemic preparedness, with possible effectiveness against Ebola/Marburg and Hendra/Nipah viruses. The company plans to pursue orphan drug status for several indications and may be eligible for Priority Review Vouchers worth $150-250 million each. NV-387's unique mechanism mimics HSPG, a cell-side molecule that over 90% of human pathogenic viruses bind to, making viral escape unlikely.

NanoViricides (NYSE Amer: NNVC) has achieved a significant breakthrough in developing NV-387, potentially the first-ever drug treatment for Measles. In a humanized animal model study, NV-387 demonstrated strong effectiveness, increasing survival time by 130% (17 days vs. 7.4 days in untreated animals) with no toxicity signs.

The broad-spectrum antiviral drug works by acting as a cell decoy, targeting 90-95% of human pathogenic viruses that require sulfated proteoglycan features. The study utilized specially modified mice bearing the human CD150/SLAM protein, necessary for measles infection. This development is particularly significant as global measles cases rise and vaccination rates decline, especially in industrialized nations.

NanoViricides (NYSE:NNVC) has responded to WHO's extension of the MPox Public Health Emergency status by highlighting the development of their drug candidate NV-387. The company is preparing for Phase II clinical trials of NV-387 for MPox treatment, following successful Phase I safety results where the drug showed no adverse events and demonstrated oral availability.

Unlike current treatments Tecovirimat and Brincidofovir, which have shown limitations and safety concerns, NV-387 employs a unique host-mimetic nanomedicine technology that viruses reportedly cannot escape. The drug achieved a No-Observed-Adverse-Event Level at 1,200 mg/kg in animal studies and is formulated as oral gummies suitable for MPox patients with oral lesions.

The company aims to target a multi-billion-dollar global market for poxvirus bioterrorism preparedness, particularly focusing on the US Strategic National Stockpile market upon successful Phase II trials.

NanoViricides (NYSE:NNVC) has nearly completed the design of an adaptive clinical trial protocol for testing NV-387, their novel broad-spectrum antiviral drug, for treating MPox Virus Clade Ia and Ib infections. The trial will involve approximately 80 patients across two phases (IIa and IIb) in the Democratic Republic of Congo.

The Phase IIa will include 20 patients (10 in treatment arm, 10 in control), while Phase IIb will involve 60 patients in a 2:1 randomization (40 treatment, 20 control). The study will use "NV-387 Oral Gummies," designed specifically for MPox patients who have difficulty swallowing due to mucosal lesions.

If successful, NV-387 would be the first effective drug for MPox treatment in human clinical trials. The company plans to pursue regulatory approvals in Africa, USA, and EU, with potential for Orphan Drug Designation in the USA. The market opportunity is significant, as demonstrated by competitor SIGA's Tecovirimat generating over $600 million in US government sales through December 2024.

NanoViricides (NYSE Amer.:NNVC) has announced plans to advance its lead drug candidate NV-387 into Phase II clinical trials, initially focusing on MPox treatment. The company has already secured a Clinical Trial Site in the Democratic Republic of Congo (DRC) and is finalizing the trial protocol.

The strategic decision to prioritize MPox is driven by several factors: the ongoing epidemic in Africa enabling timely patient recruitment, lower clinical trial costs compared to US/Europe trials, and potential inclusion in the US Strategic National Stockpile (SNS). The company notes that current approved drugs for smallpox treatment, tecovirimat (Tpoxx) and brincidofovir (Tembexa), have shown limitations in MPox treatment.

NanoViricides has developed "NV-387 Oral Gummies" as the drug delivery format, specifically designed for MPox patients who may have difficulty swallowing due to mucosal lesions. The drug substance manufacture is substantially completed at the company's facility, with drug product manufacturing in progress.

NanoViricides (NYSE: NNVC) announces that its broad-spectrum antiviral drug NV-387 could be crucial for pandemic preparedness amid rising COVID and bird flu variants. The drug has shown superior effectiveness against both COVID-19 and influenza compared to existing treatments like Remdesivir and Tamiflu. NV-387 has completed Phase I trials with no adverse events and is formulated as oral gummies. The drug targets invariant viral features, making it difficult for viruses to develop resistance. The company highlights NV-387's advantages including US-based manufacturing capabilities, room temperature storage, and potential rapid deployment for pandemic response. The drug's development comes as new COVID variant Nimbus (NB1.8.1) emerges with increased transmission and vaccine resistance, while H5N1 bird flu cases show concerning developments in Michigan and Cambodia.

NanoViricides (NYSE:NNVC) announces advancement in its Measles drug development program with an imminent animal trial using their clinical-stage drug NV-387. The study will use specially modified mice bearing human CD150/SLAM protein to evaluate drug candidates in a lethal infection model. NV-387, which previously demonstrated success in curing lethal RSV infection in animals, is designed to act as a cell decoy that destroys virus particles. This development comes amid rising measles cases, with 1,088 confirmed cases across 33 US jurisdictions in early 2025 and a ten-fold increase in European cases in 2024. The company aims to address an unmet medical need, as there are currently no approved drugs for measles treatment, while vaccination rates have declined below the 95% herd immunity threshold and vaccine failure cases are increasing due to new virus genotypes.

NanoViricides (NYSE:NNVC) will present at the BIO International Convention 2025 in Boston on June 16th at 2:30pm. The company's President, Dr. Anil R. Diwan, will provide updates on their drug pipeline and platform technologies. Their lead drug candidate, NV-387, is advancing towards Phase II trials for MPOX treatment and shows effectiveness against RSV, Influenza A, and Coronaviruses. The drug's unique mechanism mimics host-side features that 90-95% of human pathogens use, making it difficult for viruses to develop resistance. The company is also developing NV-HHV-1 for herpesvirus infections and NV-HIV-1 for HIV treatment. NanoViricides' platform enables oral drug delivery, drug rescue, and targeted delivery capabilities. The estimated market size for NV-387 indications exceeds $10 billion.

NanoViricides (NYSE:NNVC) has filed its Q1 2025 quarterly report, highlighting significant progress with its broad-spectrum antiviral drug NV-387. The company is advancing towards Phase II clinical trials for treating MPox in the Democratic Republic of Congo, following successful completion of Phase I trials with no adverse events. NV-387 has shown promising results against multiple viruses including MPox, Measles, and Bird Flu (H5N1). The company reported $2.73M in cash and $6.98M in property assets, with current liabilities of $1.20M. However, NanoViricides needs additional funding to continue operations through February 2026 for planned clinical trials. The company has access to a $3M credit line from its founder and is exploring ATM equity offerings for funding.

NV-387's unique host-mimetic mechanism makes it potentially effective against various viruses while being difficult for viruses to develop resistance, positioning it as a potentially revolutionary treatment comparable to penicillin's impact on bacterial infections.